Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Pierri

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Leukemia & Lymphoma|June 28, 2001
First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemiaM Clavio, S Gatto, G Beltrami, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 22, 1999
GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short, and effective induction treatment for de novo AML, suitable for the elderlyI Pierri, M Clavio, G Beltrami, et al.
Haematologica|November 1, 1996
High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemiaM Clavio, P Carrara, M Miglino, et al.
Leukemia & Lymphoma|July 1, 1996
Anaplastic large cell lymphoma: a clinicopathologic study of 53 patientsM Clavio, E Rossi, M Truini, et al.
Leukemia & Lymphoma|June 28, 2001
Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemiaD Russo, G Pricolo, M Michieli, et al.
European Journal of Haematology|September 30, 1998
First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual diseaseM Clavio, M Miglino, M Spriano, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 15, 2003
Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patientsM Clavio, S Gatto, G Beltrami, et al.
Bone Marrow Transplantation|October 31, 2002
Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapseM Miglino, G Berisso, R Grasso, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Leukemia & Lymphoma|June 28, 2001
First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemiaM Clavio, S Gatto, G Beltrami, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 22, 1999
GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short, and effective induction treatment for de novo AML, suitable for the elderlyI Pierri, M Clavio, G Beltrami, et al.
Haematologica|November 1, 1996
High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemiaM Clavio, P Carrara, M Miglino, et al.
Leukemia & Lymphoma|July 1, 1996
Anaplastic large cell lymphoma: a clinicopathologic study of 53 patientsM Clavio, E Rossi, M Truini, et al.
Leukemia & Lymphoma|June 28, 2001
Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemiaD Russo, G Pricolo, M Michieli, et al.
European Journal of Haematology|September 30, 1998
First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual diseaseM Clavio, M Miglino, M Spriano, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 15, 2003
Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patientsM Clavio, S Gatto, G Beltrami, et al.
Bone Marrow Transplantation|October 31, 2002
Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapseM Miglino, G Berisso, R Grasso, et al.
Pageof 5